This webinar featured Helen Rees, principal investigator of the FACTS 001 microbicide trial of vaginal 1% tenofovir gel, and Jared Baeten, co-chair of Partners PrEP.
FACTS 001, which released data at CROI, found no evidence of protection overall associated with the vaginal gel. Partners Demonstration Project, which reported data at the same meeting, found that serodiscordant couples using oral PrEP and/or ART had very low levels of HIV transmission. We discussed what these and other data meant for women, including young and adolescent girls.
Download slides and audio from the webinar.
In advance of the webinar, we suggested the following talks from CROI and excerpts from AVAC Report 2014/15 as background:
- CROI Webcast: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women
- CROI Webcast: Near Elimination of HIV Transmission in a Demonstration Project of PrEP and ART
- Excerpts from AVAC Report on microbicides and PrEP